Olmecar™ 10 Tablet: Each tablet contains Olmesartan Medoxomil EP 10 mg.
Olmecar™ 20 Tablet: Each tablet contains Olmesartan Medoxomil EP 20 mg.
Olmecar™ 40 Tablet: Each tablet contains Olmesartan Medoxomil EP 40 mg.
Olmesartan Medoxomil is a selective angiotensin II receptor antagonist (AT1 subtype). Olmesartan Medoxomil a prodrug, is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract.
Hypertension.
The starting dose is 10 mg once daily and maximum dose is 40 mg once daily. In patients whose blood pressure is not adequately controlled at the starting dose, the dose of Olmesartan medoxomil may be increased to 20 mg once daily as the optimal dose.
Pregnancy: Categories: C (rst trimester) and D (second and third trimesters). Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.
Store in a cool and dry place below 30° C. Protect from light and moisture. Keep out of the reach of children.
Olmecar™ 10 Tablet: Each box contains 30 tablets in blister pack. Olmecar™ 20 Tablet: Each box contains 30 tablets in blister pack. Olmecar™ 40 Tablet: Each box contains 30 tablets in blister pack.